Invicta Diagnostic Limited (NSE:INVICTA)
India
· Delayed Price · Currency is INR 62.00
-3.45 (-5.27%)
At close: Mar 9, 2026
Invicta Diagnostic Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| Operating Revenue | 300.95 | 158.31 | 68.43 | 29.03 | - |
| Other Revenue | 0.86 | 0.68 | - | - | - |
| Revenue | 301.81 | 158.98 | 68.43 | 29.03 | - |
| Revenue Growth (YoY) | 89.84% | 132.33% | 135.74% | - | - |
| Cost of Revenue | 23.63 | 14.67 | 9.56 | 7.93 | - |
| Gross Profit | 278.18 | 144.32 | 58.87 | 21.1 | - |
| Selling, General & Admin | 74.9 | 35.15 | 18.67 | 2.8 | - |
| Other Operating Expenses | 110.44 | 37.62 | 23 | 15.55 | 0.03 |
| Operating Expenses | 210.24 | 92.1 | 60.68 | 49.51 | 0.03 |
| Operating Income | 67.94 | 52.22 | -1.81 | -28.41 | -0.03 |
| Interest Expense | -1.61 | -0.59 | - | - | - |
| Interest & Investment Income | - | - | 0.11 | 2.14 | - |
| Other Non Operating Income (Expenses) | -0.7 | -0.42 | - | 0.03 | - |
| EBT Excluding Unusual Items | 65.64 | 51.21 | -1.7 | -26.24 | -0.03 |
| Gain (Loss) on Sale of Investments | - | - | -0 | - | - |
| Pretax Income | 65.64 | 51.21 | -1.71 | -26.24 | -0.03 |
| Income Tax Expense | 16.34 | 13.16 | - | - | - |
| Earnings From Continuing Operations | 49.3 | 38.05 | -1.71 | -26.24 | -0.03 |
| Minority Interest in Earnings | -0.38 | -0.44 | - | - | - |
| Net Income | 48.92 | 37.61 | -1.71 | -26.24 | -0.03 |
| Net Income to Common | 48.92 | 37.61 | -1.71 | -26.24 | -0.03 |
| Net Income Growth | 30.04% | - | - | - | - |
| Shares Outstanding (Basic) | 8 | 8 | - | - | - |
| Shares Outstanding (Diluted) | 8 | 8 | - | - | - |
| EPS (Basic) | 5.81 | 4.47 | - | - | - |
| EPS (Diluted) | 5.81 | 4.47 | - | - | - |
| EPS Growth | 30.04% | - | - | - | - |
| Free Cash Flow | 60.03 | -21.16 | - | - | - |
| Free Cash Flow Per Share | 7.13 | -2.51 | - | - | - |
| Gross Margin | 92.17% | 90.77% | 86.03% | 72.68% | - |
| Operating Margin | 22.51% | 32.84% | -2.65% | -97.88% | - |
| Profit Margin | 16.21% | 23.66% | -2.50% | -90.40% | - |
| Free Cash Flow Margin | 19.89% | -13.31% | - | - | - |
| EBITDA | 92.81 | 71.43 | 17.21 | 2.75 | - |
| EBITDA Margin | 30.75% | 44.93% | 25.15% | 9.47% | - |
| D&A For EBITDA | 24.87 | 19.21 | 19.02 | 31.16 | - |
| EBIT | 67.94 | 52.22 | -1.81 | -28.41 | -0.03 |
| EBIT Margin | 22.51% | 32.84% | -2.65% | -97.88% | - |
| Effective Tax Rate | 24.90% | 25.69% | - | - | - |
| Revenue as Reported | 301.81 | 158.98 | 68.54 | 31.2 | - |
| Advertising Expenses | 10.84 | 5.05 | 4.42 | - | - |
Source: S&P Capital IQ. Standard template. Financial Sources.